Skip to content

EBITDA at other companies

Guardant Health logo
Guardant HealthGH
Natera, Inc. logo
Natera, Inc.NTRA
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Revvity logo
RevvityRVTY
Labcorp Holdings logo
Labcorp HoldingsLH
Quest Diagnostics logo
Quest DiagnosticsDGX

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.28B+10.7%
Enterprise value$4.05B+7.4%
P/E48.6×-68.3×
P/S7.9×-0.4×

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0.0×
Current ratio9.3×+4.2×

Where this comes from

Calculated from Veracyte’s reported figures.

$22.6Mebit+
$5.4MDepreciation Depletion & Amortization
=$28.08M

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's EBITDA?
Veracyte (VCYT) reported EBITDA of $28.08M in Q1 2026.
How has Veracyte's EBITDA changed year-over-year?
Veracyte's EBITDA increased by 239.7% year-over-year, from $8.27M to $28.08M.
What is the long-term trend for Veracyte's EBITDA?
Over 4 years (2021 to 2025), Veracyte's EBITDA has grown at a 6.2% compound annual growth rate (CAGR), from -$62.31M to $79.19M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.